Cabazitaxel (previously XRP-6258) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. FDA for the treatment of hormone-refractory prostate cancer on June 17, 2010. It is a microtubule inhibitor, and the fourth taxane to be approved as a cancer therapy.
Cabazitaxel in combination with prednison is a treatment option for hormone-refractory prostate cancer following docetaxel-based treatment.
Cabazitaxel anticancer mechanism and characteristics similar with docetaxel, belongs to anti-microtubule drugs. Cabazitaxel through binding to tubulin, promoting their assembly into microtubules, and can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.
Product Name |
Cabazitaxel |
CAS |
183133-96-2 |
Appearance |
Off-White Powder |
Molecular formula |
C45H57NO14 |
Molecular Weight |
835.93 |
Assay |
99% |
Shelf Life |
24 months when properly stored |
Storage |
Keep in a cool, dry, dark location |
1.Cabazitaxel anticancer mechanism and characteristics similar with docetaxel, belongs to anti-microtubule drugs.
2.Cabazitaxel through binding to tubulin, promoting their assembly into microtubules,
3.It can prevent these have assembled a microtubule disintegration of the stabilization of microtubules, thereby
inhibiting cell mitosis, and interphase cellular functions (interphasecellularfunctions) of play.
Cabazitaxel's anti-cancer mechanism and characteristics are similar to docetaxel and belong to anti-microtubule drugs. Cabazitaxel promotes its assembly into microtubules by binding to tubulin, while preventing the disassembly of these assembled microtubules, stabilizing microtubules, thereby inhibiting cell mitosis, and interphase cellular functions.